Cinepathy: A translational framework bridging neurocinematics and clinical therapy

Neurocinematics has described how the brain responds to cinema, though responses vary with mental state, prior experience, and cultural background, blurring therapeutic and personal effects. No standardized, neurobiologically grounded therapeutic framework has yet been derived from that literature. We introduce Cinepathy to address this gap.

Cinepathy proposes that cinema modulates neural activity through six convergent mechanisms, proposed to operate in concert: sensory-emotional association, narrative involvement, embodied simulation, limbic activation, neurohormonal regulation, and dopaminergic modulation.

We propose that systematically selected film stimuli may engage distinct neural circuits reproducibly. That cinematic stimulation can produce therapeutic benefit is our central hypothesis and not a demonstrated result. fMRI and EEG studies show neural synchronization across viewers during emotional peaks and narrative climaxes. Meta-analytic and randomized evidence indicates that receptive sensory interventions reduce self-reported anxiety, though effects on physiological measures are not established. We propose ¹ ¹C-PHNO PET, which images dopamine D2/D3 receptors, to test whether emotionally charged scenes evoke dopaminergic release; whether that release is large enough for reliable measurement is unknown. Because mesolimbic and mesocortical circuits are implicated in trauma and emotional dysregulation, Cinepathy is advanced as a candidate non-invasive therapeutic framework whose clinical efficacy requires empirical evaluation.

Cinepathy positions therapeutic film use within systems neuroscience. This framework's mechanistic predictions can be tested using fMRI, EEG, and ¹ ¹C-PHNO PET alongside autonomic measures, including heart rate variability, skin conductance, and pupillometry. It positions cinema as a reproducible stimulus for neuroscientific study and outlines a path toward standardized clinical trials.